- Tempus AI reported Q3 2026 revenue of US$411.54 million and a net loss of US$14.85 million. The company then raised full year 2026 revenue guidance to a range of US$1.60 billion to US$1.605 billion and signed multi year data agreements with Bristol Myers Squibb and Pathos AI.
- The Pathos AI collaboration, which includes a five year US$55 million data licensing deal for neurological datasets, highlights how Tempus AI is extending its oncology data infrastructure into neuroscience while deepening long term relationships with large pharmaceutical clients.
- We will examine how Tempus AI's higher 2026 revenue guidance affects the existing investment narrative built around data scale and partnerships.
See how Tempus AI’s pharma data deals compare with other AI-driven healthcare plays by reviewing the hand picked 38 healthcare AI stocks now gaining traction with major partners.
Tempus AI Investment Narrative Recap
For a shareholder in Tempus AI, the core belief is that its mix of diagnostics, multimodal data and AI tools can scale into a durable healthcare platform. The latest quarter keeps that thesis intact. Revenue reached US$411.54 million, losses narrowed to US$14.85 million, and management lifted 2026 revenue guidance to a range of US$1.60 billion to US$1.605 billion, pointing to stronger near term demand visibility.
The key short term catalyst remains execution on high margin data and applications contracts while continuing to reduce losses. The biggest risk is still the heavy investment burden and reliance on pharma and biotech budgets in a competitive AI and genomics market. The new results and guidance materially support the catalyst without removing that risk.
The most relevant update for that catalyst is Tempus AI’s multi year data agreement with Bristol Myers Squibb. BMS will license multimodal oncology data through 2031 and use the Lens platform to support target discovery, clinical insight and drug development. This sits directly in the firm’s higher value data and applications segment.
That agreement, alongside the separate US$55 million, five year licensing deal with Pathos AI for neurological datasets, increases contracted visibility on data revenue and validates demand for Tempus AI’s infrastructure beyond oncology. Execution risk does not disappear, because pharma R&D budgets and competitive offerings can still shift, but these deals strengthen the operational backdrop for the coming years.
Tempus AI’s narrative projects US$2.6b revenue and US$435.3 million earnings by 2029. Analysts model 22.6% yearly revenue growth and an earnings increase of about US$689.7 million, from current earnings of a US$254.4 million loss.
Uncover why Tempus AI's fair value is in line with its current price.
Exploring Other Perspectives
One alternate view around Tempus AI focuses less on new pharma deals and more on whether its large data and hardware spending can truly pay off. The most cautious analysts were using only 19.6% expected annual revenue growth and earnings of about US$419.2 million by 2029. Those pre‑news assumptions are far more restrained, so you can compare both narratives and decide which better matches your expectations.
Explore 5 other Tempus AI fair value estimates, including one that suggests as much as 51% downside from the current price!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own analysis and judgment.
- A great starting point for your Tempus AI research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- See our latest analysis for Tempus AI. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Tempus AI's overall financial health at a glance.
Looking For More Investment Ideas Beyond Tempus AI?
If the Tempus AI story has sharpened your appetite for data rich opportunities, it can help to line it up against a wider watchlist built around clear fundamentals and risk profiles.
Use the Simply Wall St Screener to source ideas that fit your own approach, whether you care most about value, balance sheet strength or lower volatility.
- For investors who want quality at a reasonable price, review a curated 34 high quality undervalued stocks that combine strong fundamentals with discounted valuations.
- If capital preservation matters most, focus on stability first and check out a 31 resilient stocks with low risk scores that screens for resilient businesses with healthier risk profiles.
- To uncover potential future leaders before they gain wider attention, scan through a 19 high quality undiscovered gems with solid financial metrics and room to grow.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com